Yosuke Seki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yosuke Seki has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
Kazunori Kasama
Weight Loss and Metabolic Surgery Center, Yotsuya Medical Cube, Tokyo, Japan
16 shared publicationsYoshimochi Kurokawa
Department of Surgery, Yotsuya Medical Cube, Tokyo, Japan
15 shared publicationsAkiko Umezawa
Weight Loss and Metabolic Surgery Center, Yotsuya Medical Cube, 7-7 Nibancho, Chiyoda-ku, Tokyo, 102-0084, Japan
7 shared publicationsRenzo Yokoyama
Weight Loss and Metabolic Surgery Center, Yotsuya Medical Cube, Tokyo, Japan
5 shared publications- Wah Yang
First Affiliated Hospital of Jinan University, Guangzhou, China
5 shared publications Kohei Uno
Weight Loss and Metabolic Surgery Center, Yotsuya Medical Cube, 7-7 Nibancho, Chiyoda-ku, Tokyo, 102-0084, Japan
4 shared publications
Latest Publications
- 6 November 2026
- Published by Springer Nature in Obesity Surgery
- p. 1-13
Total Small Bowel Length and Limb-length Decision-making in Metabolic and Bariatric Surgery for Asian Populations: An APMBSS 2026 Modified Delphi Expert Consensus Statement
Introduction Total small bowel length (TSBL) varies substantially and may modify the physiological effect of intestinal bypass in metabolic and bariatric surgery (MBS). Fixed limb lengths do not account for individual variation and may contribute to suboptimal metabolic effect or excessive malabsorption. Methods The APMBSS 2026 TSBL Consensus Panel used a two-round modified Delphi process. Faculty rated 38 statements across seven domains on a 5-point Likert scale. Thirty-five statements reached consensus in Round 1 and were reaffirmed during faculty review at the congress without repeat scoring; only three were revised and revoted. Consensus required a median score of at least 4 and at least 80% of ratings at 4 or 5; strong consensus required at least 90% agreement. Results Forty-one analyzable responses from 15 countries/regions were included in Round 1. Thirty-five statements reached consensus. Three statements were discussed, revised, and revoted; one additional statement reached consensus. Overall, 36 of 38 statements achieved consensus (30 strong, 6 consensus). No final consensus was reached on routine TSBL measurement during standard sleeve gastrectomy or on diminishing metabolic returns beyond a 150-cm biliopancreatic limb in Roux-en-Y gastric bypass. Conclusion The consensus supports standardized measurement and documentation of TSBL and procedure-specific limb lengths in bypass-based procedures. It does not prescribe a universal limb-length formula, but establishes a framework for interpreting bypass physiology, balancing metabolic efficacy and nutritional safety, and evaluating TSBL-adjusted strategies in Asian registries and prospective studies. Key Points • TSBL provides an anatomical denominator for interpreting intestinal bypass. • Standardized TSBL and limb-length documentation was supported by the panel. • No universal TSBL-adjusted limb-length formula was supported. • The panel supported a minimum 300-cm common channel for SADI-S in Asian populations.
- 6 November 2026
- Published by Springer Nature in Obesity Surgery
- p. 1-13
Total Small Bowel Length and Limb-length Decision-making in Metabolic and Bariatric Surgery for Asian Populations: An APMBSS 2026 Modified Delphi Expert Consensus Statement
Introduction Total small bowel length (TSBL) varies substantially and may modify the physiological effect of intestinal bypass in metabolic and bariatric surgery (MBS). Fixed limb lengths do not account for individual variation and may contribute to suboptimal metabolic effect or excessive malabsorption. Methods The APMBSS 2026 TSBL Consensus Panel used a two-round modified Delphi process. Faculty rated 38 statements across seven domains on a 5-point Likert scale. Thirty-five statements reached consensus in Round 1 and were reaffirmed during faculty review at the congress without repeat scoring; only three were revised and revoted. Consensus required a median score of at least 4 and at least 80% of ratings at 4 or 5; strong consensus required at least 90% agreement. Results Forty-one analyzable responses from 15 countries/regions were included in Round 1. Thirty-five statements reached consensus. Three statements were discussed, revised, and revoted; one additional statement reached consensus. Overall, 36 of 38 statements achieved consensus (30 strong, 6 consensus). No final consensus was reached on routine TSBL measurement during standard sleeve gastrectomy or on diminishing metabolic returns beyond a 150-cm biliopancreatic limb in Roux-en-Y gastric bypass. Conclusion The consensus supports standardized measurement and documentation of TSBL and procedure-specific limb lengths in bypass-based procedures. It does not prescribe a universal limb-length formula, but establishes a framework for interpreting bypass physiology, balancing metabolic efficacy and nutritional safety, and evaluating TSBL-adjusted strategies in Asian registries and prospective studies. Key Points • TSBL provides an anatomical denominator for interpreting intestinal bypass. • Standardized TSBL and limb-length documentation was supported by the panel. • No universal TSBL-adjusted limb-length formula was supported. • The panel supported a minimum 300-cm common channel for SADI-S in Asian populations.
- 27 November 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 173-181
Ten-Year Outcomes of Laparoscopic Sleeve Gastrectomy with Roux-en-Y Duodenojejunal Bypass on Weight Loss, Metabolic Syndrome, and Nutrition: A Retrospective Cohort Study
Objective To report the 10-year outcomes of laparoscopic sleeve gastrectomy with Roux-en-Y duodenojejunal bypass (LSG-DJB) on weight loss, resolution of associated medical problems, and nutritional status. Background LSG-DJB is an established metabolic procedure as an alternative to laparoscopic Roux-en-Y gastric bypass (LRYGB), especially in Asia, where the incidence of gastric cancer is relatively high, but long-term data are limited. Methods A retrospective study conducted at a single center involving 177 patients who underwent LSG-DJB, with follow-up data available for up to 10 years. Outcomes measured included weight loss, remission rates of T2DM, hypertension, dyslipidemia, and nutritional markers. Results Durable weight loss was maintained over 8–10 years, with %TWL of 28.9% and %EWL of 93.1%. The remission rates at 8–10 years were 35.5% for T2DM, 39.1% for hypertension, and 48.1% for dyslipidemia. Liver enzyme and uric acid levels also showed significant, sustained improvements. The rate of conversion surgery was low (4%), with no cases of severe malnutrition. The prevalence of anemia increased to 25%, although the mean hemoglobin and iron levels remained stable. Conclusions This is the first report on the long-term outcomes of LSG-DJB. It shows sustained weight loss and control of associated medical problems at 8–10 years, aligning with published data on RYGB. It effectively prevents severe malnutrition but requires monitoring for anemia. These findings confirm the long-term effectiveness and nutritional safety of LSG-DJB and provide strong support for future RCTs that directly compare it to other procedures over more extended follow-up periods.
- 27 November 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 173-181
Ten-Year Outcomes of Laparoscopic Sleeve Gastrectomy with Roux-en-Y Duodenojejunal Bypass on Weight Loss, Metabolic Syndrome, and Nutrition: A Retrospective Cohort Study
Objective To report the 10-year outcomes of laparoscopic sleeve gastrectomy with Roux-en-Y duodenojejunal bypass (LSG-DJB) on weight loss, resolution of associated medical problems, and nutritional status. Background LSG-DJB is an established metabolic procedure as an alternative to laparoscopic Roux-en-Y gastric bypass (LRYGB), especially in Asia, where the incidence of gastric cancer is relatively high, but long-term data are limited. Methods A retrospective study conducted at a single center involving 177 patients who underwent LSG-DJB, with follow-up data available for up to 10 years. Outcomes measured included weight loss, remission rates of T2DM, hypertension, dyslipidemia, and nutritional markers. Results Durable weight loss was maintained over 8–10 years, with %TWL of 28.9% and %EWL of 93.1%. The remission rates at 8–10 years were 35.5% for T2DM, 39.1% for hypertension, and 48.1% for dyslipidemia. Liver enzyme and uric acid levels also showed significant, sustained improvements. The rate of conversion surgery was low (4%), with no cases of severe malnutrition. The prevalence of anemia increased to 25%, although the mean hemoglobin and iron levels remained stable. Conclusions This is the first report on the long-term outcomes of LSG-DJB. It shows sustained weight loss and control of associated medical problems at 8–10 years, aligning with published data on RYGB. It effectively prevents severe malnutrition but requires monitoring for anemia. These findings confirm the long-term effectiveness and nutritional safety of LSG-DJB and provide strong support for future RCTs that directly compare it to other procedures over more extended follow-up periods.
- Open Access
- 16 January 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (2) , 471-480
Reversal of Roux-en-Y Gastric Bypass: A Multi-Centric Analysis of Indications, Techniques, and Surgical Outcomes
Background: Roux-en-Y gastric bypass may present long-term complications that require revisional surgery or even reversal to normal anatomy. Data on the indications, surgical technique, and outcomes of RYGB reversal remain scarce. Methods: We identified 48 cases of RYGB reversals with complete 90-day follow-up within a multi-centric international retrospective database of elective secondary bariatric surgery. The operations were performed between 2010 and 2024 in high-volume referral centers in Europe and USA. Data were collected on body weight, associated diseases, and on surgical outcomes up to 1-year postoperatively. Results: Patients were mainly female (81.3%) with a median age of 50 years (IQR 39–56). RYGB reversal was performed 7 years (median) after primary RYGB in patients with a BMI of 23.9 kg/m2 (IQR 20–27). Half of the patients underwent at least 1 bariatric revision before the reversal. Main indications for reversal were dumping syndrome (33.3%), excessive weight loss (29.2%), marginal ulcer (14.6%), malabsorption (12.5%), and abdominal pain (10.4%). Rate of conversion to open surgery was 8.3%, and the postoperative complications during the first year reached 50%, including 31.3% Clavien-Dindo grade I–II, 16.7% grade III–IV complications, and one death. At 1 year, the mean BMI of the cohort increased by 18% to 28.25 kg/m2; only 1 patient reached pre-RYGB BMI. Conclusion: Although RYGB is a theoretically reversible procedure, normal anatomy is re-established only in selected cases which are refractory to medical therapy and often also to revisional bariatric surgery. RYGB reversals entail high morbidity, while the extent of recurrent weight gain at 1-year post-reversal seems to allow patients to remain below the threshold of severe obesity.
- 16 January 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (2) , 471-480
Open AccessReversal of Roux-en-Y Gastric Bypass: A Multi-Centric Analysis of Indications, Techniques, and Surgical Outcomes
Background: Roux-en-Y gastric bypass may present long-term complications that require revisional surgery or even reversal to normal anatomy. Data on the indications, surgical technique, and outcomes of RYGB reversal remain scarce. Methods: We identified 48 cases of RYGB reversals with complete 90-day follow-up within a multi-centric international retrospective database of elective secondary bariatric surgery. The operations were performed between 2010 and 2024 in high-volume referral centers in Europe and USA. Data were collected on body weight, associated diseases, and on surgical outcomes up to 1-year postoperatively. Results: Patients were mainly female (81.3%) with a median age of 50 years (IQR 39–56). RYGB reversal was performed 7 years (median) after primary RYGB in patients with a BMI of 23.9 kg/m2 (IQR 20–27). Half of the patients underwent at least 1 bariatric revision before the reversal. Main indications for reversal were dumping syndrome (33.3%), excessive weight loss (29.2%), marginal ulcer (14.6%), malabsorption (12.5%), and abdominal pain (10.4%). Rate of conversion to open surgery was 8.3%, and the postoperative complications during the first year reached 50%, including 31.3% Clavien-Dindo grade I–II, 16.7% grade III–IV complications, and one death. At 1 year, the mean BMI of the cohort increased by 18% to 28.25 kg/m2; only 1 patient reached pre-RYGB BMI. Conclusion: Although RYGB is a theoretically reversible procedure, normal anatomy is re-established only in selected cases which are refractory to medical therapy and often also to revisional bariatric surgery. RYGB reversals entail high morbidity, while the extent of recurrent weight gain at 1-year post-reversal seems to allow patients to remain below the threshold of severe obesity.
- 7 August 2024
- Published by Springer Nature in Current Obesity Reports
- Vol. 13 (4) , 818-830
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
Purpose of Review The approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed. Recent Findings Resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted. Summary MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.
- 7 August 2024
- Published by Springer Nature in Current Obesity Reports
- Vol. 13 (4) , 818-830
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
Purpose of Review The approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed. Recent Findings Resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted. Summary MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.
- 1 July 2024
- Published by Elsevier in Obesity Research & Clinical Practice
- Vol. 18 (3) , 195-200
30-day morbidity and mortality of revisional bariatric surgery – An international multi-centre collaborative (BROAD) study
- 1 July 2024
- Published by Elsevier in Obesity Research & Clinical Practice
- Vol. 18 (3) , 195-200
30-day morbidity and mortality of revisional bariatric surgery – An international multi-centre collaborative (BROAD) study
- Open Access
- 7 February 2023
- Published by S. Karger AG in Obesity Facts
- Vol. 16 (2) , 119-130
Factors Associated with Relapse of Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy in Japanese Subjects: A Subgroup Analysis of J-SMART Study
Introduction: Laparoscopic sleeve gastrectomy (LSG) for morbidly obese patients often results in remission of type 2 diabetes (T2DM), but diabetes relapses in some of those patients. The frequency of T2DM relapse in Asians and the factors involved have not been adequately investigated. Methods: The J-SMART study was conducted on 322 Japanese subjects with body mass index (BMI) ≥32 kg/m2 who underwent LSG at 10 accredited centers in Japan between 2011 and 2014. Of these, 82 T2DM subjects with diabetes in complete or partial remission at 1 year after LSG and followed postoperatively for 5 years were included in the subgroup analysis and classified into two groups: diabetes remission-maintained and diabetes relapse. Results: The mean age of all included subjects was 49.2 years, median BMI was 41.5 kg/m2, and median HbA1c was 6.7%. Compared with the diabetes remission-maintained group, the diabetes relapse group at 5 years after LSG had significantly higher preoperative HbA1c, number of antidiabetic medications, and high-density lipoprotein cholesterol level; and lower BMI and homeostasis model assessment-beta cell function (HOMA-β). As many as 83.0% of the subjects were able to achieve HbA1c <7% at 5 years after LSG, but 26.8% of the subjects had diabetes relapse. Preoperative HbA1c significantly contributed to diabetes relapse (odds ratio 1.54, p = 0.049). In addition, the diabetes relapse group tended to have lower percentage total weight loss (%TWL) at 1 year after LSG and higher percentage weight regain (%WR) from postoperative nadir weight, compared with the diabetes remission-maintained group. The hazard ratio for diabetes relapse was 3.14-fold higher in subjects with %TWL ≥20% and %WR ≥25%, and 5.46-fold higher in those with %TWL <20% and %WR ≥25%, compared with %TWL ≥20% and %WR <25%. Conclusion: While LSG provides a high remission rate for T2DM, relapse is not uncommon. Preoperative HbA1c, poor weight loss, and excess weight regain after LSG contribute to diabetes relapse, suggesting the importance of treatment strategies focusing on these factors.
- 7 February 2023
- Published by S. Karger AG in Obesity Facts
- Vol. 16 (2) , 119-130
Open AccessFactors Associated with Relapse of Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy in Japanese Subjects: A Subgroup Analysis of J-SMART Study
Introduction: Laparoscopic sleeve gastrectomy (LSG) for morbidly obese patients often results in remission of type 2 diabetes (T2DM), but diabetes relapses in some of those patients. The frequency of T2DM relapse in Asians and the factors involved have not been adequately investigated. Methods: The J-SMART study was conducted on 322 Japanese subjects with body mass index (BMI) ≥32 kg/m2 who underwent LSG at 10 accredited centers in Japan between 2011 and 2014. Of these, 82 T2DM subjects with diabetes in complete or partial remission at 1 year after LSG and followed postoperatively for 5 years were included in the subgroup analysis and classified into two groups: diabetes remission-maintained and diabetes relapse. Results: The mean age of all included subjects was 49.2 years, median BMI was 41.5 kg/m2, and median HbA1c was 6.7%. Compared with the diabetes remission-maintained group, the diabetes relapse group at 5 years after LSG had significantly higher preoperative HbA1c, number of antidiabetic medications, and high-density lipoprotein cholesterol level; and lower BMI and homeostasis model assessment-beta cell function (HOMA-β). As many as 83.0% of the subjects were able to achieve HbA1c <7% at 5 years after LSG, but 26.8% of the subjects had diabetes relapse. Preoperative HbA1c significantly contributed to diabetes relapse (odds ratio 1.54, p = 0.049). In addition, the diabetes relapse group tended to have lower percentage total weight loss (%TWL) at 1 year after LSG and higher percentage weight regain (%WR) from postoperative nadir weight, compared with the diabetes remission-maintained group. The hazard ratio for diabetes relapse was 3.14-fold higher in subjects with %TWL ≥20% and %WR ≥25%, and 5.46-fold higher in those with %TWL <20% and %WR ≥25%, compared with %TWL ≥20% and %WR <25%. Conclusion: While LSG provides a high remission rate for T2DM, relapse is not uncommon. Preoperative HbA1c, poor weight loss, and excess weight regain after LSG contribute to diabetes relapse, suggesting the importance of treatment strategies focusing on these factors.
- 4 February 2023
- Published by Springer Nature
- p. 23-29
Anti-reflux Surgery to Extra-esophageal Manifestations of GERD
- 4 February 2023
- Published by Springer Nature
- p. 23-29
Anti-reflux Surgery to Extra-esophageal Manifestations of GERD
- Open Access
- 30 June 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (9) , 2994-3004
Ten Years of Change in Bariatric/Metabolic Surgery in the Asia–Pacific Region with COVID-19 Pandemic: IFSO-APC National Reports 2021
Background: On November 25, 2021, the IFSO-Asia–Pacific Chapter (IFSO-APC) Virtual Meeting 2021 was held online, and the representatives from the Asia–Pacific region presented 10 years of change in bariatric/metabolic surgery and the influence of COVID-19 in the special session of “IFSO-APC National Reports 2010–2020”. We herein report the summarized data. Methods: National bariatric/metabolic surgery data, which included the data of 2010 and 2020, were collected from the representatives using a questionnaire that consisted of 10 general questions. At the congress, the data were calculated and summarized. Results: Thirteen of the 14 national societies responded to the survey. From 2010 to recent years, the populations of individuals with obesity (BMI ≥ 30 kg/m2) and individuals with diabetes both significantly increased. Eight countries and regions expanded the lower limit of criteria for bariatric surgery by 2–5 kg/m2 (BMI), and 5 countries newly established criteria for metabolic surgery in the last ten years. Sixty-nine percent of the countries currently run public health insurance systems, which doubled from 2010. The number of bariatric surgeons and institutions increased more than threefold from 2010. In 2010, 2019, and 2020, surgeons in IFSO-APC societies performed 18,280, 66,010, and 49,553 bariatric/metabolic surgeries, respectively. Due to the COVID pandemic, restriction policies significantly reduced access to surgery in South and Southeast Asian countries. The biggest changes included increased numbers of bariatric surgeons and institutions, operation numbers, public insurance coverage, raising awareness, and national registry systems. Conclusion: For the last 10 years, bariatric/metabolic surgery has rapidly grown in the Asia–Pacific region.
- 30 June 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (9) , 2994-3004
Open AccessTen Years of Change in Bariatric/Metabolic Surgery in the Asia–Pacific Region with COVID-19 Pandemic: IFSO-APC National Reports 2021
Background: On November 25, 2021, the IFSO-Asia–Pacific Chapter (IFSO-APC) Virtual Meeting 2021 was held online, and the representatives from the Asia–Pacific region presented 10 years of change in bariatric/metabolic surgery and the influence of COVID-19 in the special session of “IFSO-APC National Reports 2010–2020”. We herein report the summarized data. Methods: National bariatric/metabolic surgery data, which included the data of 2010 and 2020, were collected from the representatives using a questionnaire that consisted of 10 general questions. At the congress, the data were calculated and summarized. Results: Thirteen of the 14 national societies responded to the survey. From 2010 to recent years, the populations of individuals with obesity (BMI ≥ 30 kg/m2) and individuals with diabetes both significantly increased. Eight countries and regions expanded the lower limit of criteria for bariatric surgery by 2–5 kg/m2 (BMI), and 5 countries newly established criteria for metabolic surgery in the last ten years. Sixty-nine percent of the countries currently run public health insurance systems, which doubled from 2010. The number of bariatric surgeons and institutions increased more than threefold from 2010. In 2010, 2019, and 2020, surgeons in IFSO-APC societies performed 18,280, 66,010, and 49,553 bariatric/metabolic surgeries, respectively. Due to the COVID pandemic, restriction policies significantly reduced access to surgery in South and Southeast Asian countries. The biggest changes included increased numbers of bariatric surgeons and institutions, operation numbers, public insurance coverage, raising awareness, and national registry systems. Conclusion: For the last 10 years, bariatric/metabolic surgery has rapidly grown in the Asia–Pacific region.
- 1 April 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (6) , 1831-1841
Long-term Impact of Laparoscopic Sleeve Gastrectomy on Drug Costs of Japanese Patients with Obesity and Type 2 Diabetes Mellitus
Purpose Laparoscopic sleeve gastrectomy (LSG) is the most common type of bariatric surgery in Japan, and it is the only such procedure covered by national health insurance. The long-term cost of bariatric surgery in Japan has not yet been analyzed. We aimed to evaluate the long-term impact of LSG on the drug treatment costs of patients with type 2 diabetes mellitus (T2DM). Materials and Methods We retrospectively analyzed data from 230 patients who had undergone LSG at our institution for their obesity and T2DM between 2007 and 2018. The clinicopathological data included age, sex, body mass index (BMI), as well as preoperative and postoperative medications for T2DM, hypertension, and dyslipidemia. We then calculated the drug treatment costs for T2DM, hypertension, and dyslipidemia before and after LSG; and we evaluated the remission rates of these obesity-related diseases. Results The median preoperative body weight and BMI of the 230 patients who underwent LSG were 115 kg and 40.6 kg/m2, respectively. Preoperative drug treatment costs per month per patient for T2DM, hypertension, and dyslipidemia were ¥3795 (¥0–40285), ¥3269 (¥0–14577), and ¥1428 (¥0–19464). Post-operation, the median drug treatment costs for all these diseases became nil. The remission rates of T2DM, hypertension, and dyslipidemia 5 years after LSG were 82.8%, 50%, and 43.8%, respectively. In Japan, the cost of an LSG operation corresponds to 4.75 years of median drug costs to treat T2DM and hypertension. Conclusion In the long term, LSG in Japan is effective both physically and cost-wise for patients with obesity and T2DM. Graphical abstract
- 1 April 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (6) , 1831-1841
Long-term Impact of Laparoscopic Sleeve Gastrectomy on Drug Costs of Japanese Patients with Obesity and Type 2 Diabetes Mellitus
Purpose Laparoscopic sleeve gastrectomy (LSG) is the most common type of bariatric surgery in Japan, and it is the only such procedure covered by national health insurance. The long-term cost of bariatric surgery in Japan has not yet been analyzed. We aimed to evaluate the long-term impact of LSG on the drug treatment costs of patients with type 2 diabetes mellitus (T2DM). Materials and Methods We retrospectively analyzed data from 230 patients who had undergone LSG at our institution for their obesity and T2DM between 2007 and 2018. The clinicopathological data included age, sex, body mass index (BMI), as well as preoperative and postoperative medications for T2DM, hypertension, and dyslipidemia. We then calculated the drug treatment costs for T2DM, hypertension, and dyslipidemia before and after LSG; and we evaluated the remission rates of these obesity-related diseases. Results The median preoperative body weight and BMI of the 230 patients who underwent LSG were 115 kg and 40.6 kg/m2, respectively. Preoperative drug treatment costs per month per patient for T2DM, hypertension, and dyslipidemia were ¥3795 (¥0–40285), ¥3269 (¥0–14577), and ¥1428 (¥0–19464). Post-operation, the median drug treatment costs for all these diseases became nil. The remission rates of T2DM, hypertension, and dyslipidemia 5 years after LSG were 82.8%, 50%, and 43.8%, respectively. In Japan, the cost of an LSG operation corresponds to 4.75 years of median drug costs to treat T2DM and hypertension. Conclusion In the long term, LSG in Japan is effective both physically and cost-wise for patients with obesity and T2DM. Graphical abstract
- Top Cited Papers
- 26 December 2021
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 15 (2) , 415-426
Current Status of Endoscopic Surgery in Japan: The 15th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery
In Japan, the first endoscopic surgery, a laparoscopic cholecystectomy, was performed in 1990. Since then, operative procedures have been standardized, and the safety and efficacy of endoscopic surgery have been evaluated. In accordance with the social acceptance of endoscopic surgery as a less invasive type of surgery, the number of endoscopic procedures performed has increased in all surgical domains. The Japan Society for Endoscopic Surgery (JSES) has played an important role in the development of endoscopic surgery in Japan. Notably, a technical skills certification system for surgeons was established by the JSES to train instructors on how to teach safe endoscopic surgery. Furthermore, the JSES has conducted a national survey every 2 years. In 2019, 291,792 patients underwent endoscopic surgery in all surgical domains, such as abdominal, thoracic, mammary and thyroid gland, cardiovascular, obstetrics and gynecology, urologic, orthopedic, and plastic surgery. The 15th National Survey of Endoscopic Surgery conducted by the JSES demonstrated the status of laparoscopic surgery in Japan in 2018–2019.
- 26 December 2021
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 15 (2) , 415-426
Top Cited PapersCurrent Status of Endoscopic Surgery in Japan: The 15th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery
In Japan, the first endoscopic surgery, a laparoscopic cholecystectomy, was performed in 1990. Since then, operative procedures have been standardized, and the safety and efficacy of endoscopic surgery have been evaluated. In accordance with the social acceptance of endoscopic surgery as a less invasive type of surgery, the number of endoscopic procedures performed has increased in all surgical domains. The Japan Society for Endoscopic Surgery (JSES) has played an important role in the development of endoscopic surgery in Japan. Notably, a technical skills certification system for surgeons was established by the JSES to train instructors on how to teach safe endoscopic surgery. Furthermore, the JSES has conducted a national survey every 2 years. In 2019, 291,792 patients underwent endoscopic surgery in all surgical domains, such as abdominal, thoracic, mammary and thyroid gland, cardiovascular, obstetrics and gynecology, urologic, orthopedic, and plastic surgery. The 15th National Survey of Endoscopic Surgery conducted by the JSES demonstrated the status of laparoscopic surgery in Japan in 2018–2019.